Across TCGA pan-cancer cohorts, IGHV3-33 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGHV3-33 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher IGHV3-33 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV3-33 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

DLBC, GBM, and SKCM are the cancer types where IGHV3-33 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	6	view →
GBM	DFS	Median	All	0.052	0.257	.002	6	view →
SKCM	OS	Median	II,III,IV	1.000	0.371	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGHV3-33 tumor-vs-normal RNA expression · all IGHV3-33 data types